Sort   by:  
 Page size 
UnknownImmunotherapy for Biliary Tract Cancer in the Era of Precision Medicine: Current Knowledge and Future Perspectives.
Not available
S-EPMC8775359 | biostudies-literature
UnknownInitial molecular response at 3 months may predict both response and event-free survival at 24 months in imatinib-resistant or -intolerant patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase treated with nilotinib.
Not available
S-EPMC4979159 | biostudies-literature
UnknownThe cost-effectiveness of transcatheter aortic valve implantation: exploring the Italian National Health System perspective and different patient risk groups.
Not available
S-EPMC8558181 | biostudies-literature
UnknownRituximab Maintenance for a Maximum of 5 Years After Single-Agent Rituximab Induction in Follicular Lymphoma: Results of the Randomized Controlled Phase III Trial SAKK 35/03.
Not available
S-EPMC4872010 | biostudies-literature
UnknownSkin Toxicity as Predictor of Survival in Refractory Patients with RAS Wild-Type Metastatic Colorectal Cancer Treated with Cetuximab and Avelumab (CAVE) as Rechallenge Strategy.
Not available
S-EPMC8616320 | biostudies-literature
UnknownProspective evaluation of pregnancy outcome in an Italian woman with late-onset combined homocystinuria and methylmalonic aciduria.
Not available
S-EPMC6716909 | biostudies-literature
UnknownPositivity, daily time use, mood, and functioning in patients with schizophrenia spectrum disorders: Results from the diapason multicentric study.
Not available
S-EPMC10913309 | biostudies-literature
UnknownCAVE-2 (Cetuximab-AVElumab) mCRC: A Phase II Randomized Clinical Study of the Combination of Avelumab Plus Cetuximab as a Rechallenge Strategy in Pre-Treated RAS/BRAF Wild-Type mCRC Patients.
Not available
S-EPMC9272566 | biostudies-literature
UnknownCetuximab Rechallenge Plus Avelumab in Pretreated Patients With RAS Wild-type Metastatic Colorectal Cancer: The Phase 2 Single-Arm Clinical CAVE Trial.
Not available
S-EPMC8531995 | biostudies-literature
UnknownGenomic Profiling of KRAS/NRAS/BRAF/PIK3CA Wild-Type Metastatic Colorectal Cancer Patients Reveals Novel Mutations in Genes Potentially Associated with Resistance to Anti-EGFR Agents.
Not available
S-EPMC6627713 | biostudies-literature
Sort   by:  
 Page size